Physician profile
Johnathan Leck
NPI 1720428246
$1,799.97
in general payments reported to CMS, 2019-2025
26 companies · $285 in 2025
The $285 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $52.77 · 2020: $195 · 2021: $354 · 2022: $239 · 2023: $313 · 2024: $361 · 2025: $285.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $959.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $958.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $414.19 | 2020-2025 | |
| Lilly USA, LLC | $156.08 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $154.77 | 2021-2025 | Otezla, Repatha, Otezla |
| Pfizer INC. | $145.94 | 2019-2025 | |
| Allergan, INC. | $141.35 | 2019-2020 | |
| Novo Nordisk INC | $95.72 | 2020-2024 | Wegovy |
| Abbott Laboratories | $91.95 | 2021-2022 | |
| Astellas Pharma US INC | $90.21 | 2021-2025 | Veozah |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $76.48 | 2022-2025 | Xifaxan |
| Otsuka America Pharmaceutical, INC. | $62.17 | 2022-2025 | Nuedexta, Rexulti |
| Boehringer Ingelheim Pharmaceuticals, INC. | $60.02 | 2022-2024 | Jardiance |
| Biohaven Pharmaceutical Holding Company LTD. | $49.74 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $35.89 | 2023 | Eliquis |
| Axsome Therapeutics, INC. | $30.27 | 2024-2025 | Auvelity |
| Esperion Therapeutics, INC. | $22.15 | 2021 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $19.95 | 2023 | Keveyis |
| Genentech USA, INC. | $19.48 | 2021 | |
| Supernus Pharmaceuticals, INC. | $18.96 | 2024 | Qelbree |
| Novavax INC | $16.33 | 2023 | Novavax Covid-19 Vaccine, Adjuvanted |
| Sanofi Pasteur INC. | $14.96 | 2022 | |
| Glaxosmithkline, LLC. | $14.65 | 2024 | Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals LP | $14.02 | 2021 | |
| Eisai INC. | $13.95 | 2021 | |
| Sanofi-Aventis U.S. LLC | $13.85 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $13.80 | 2021 | |
| Amarin Pharma, INC. | $13.09 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Johnathan Leck listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.